← Leaderboards
Priya S. Kishnani
Duke University
$1,826,678
Attributed
$2,115,436
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $354.4K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,115,436 · 9
By mechanism
U54$945,365 · 3
R21$433,137 · 1
K23$335,999 · 1
P41$303,472 · 1
M01$97,463 · 3
Top collaborators
- Gregory E Crawford2 shared
- Timothy E Reddy2 shared
Most similar at Duke University
Same institution · by research overlap
- Dwight D Koeberl$10,403,079
- Yuan T Chen$792,683
- Priya S Kishnani$685,042
- Nenad Bursac$22,509,345
- Vandana Shashi$14,579,906
Others in their field
Top investigators on “Cognition”
- David R. Weir · University Of Michigan At Ann Arbor$380,402,429
- Paul S. Aisen · Cognition Therapeutics, Inc.$185,453,129
- Randall J Bateman · Washington University$179,917,643
- Reisa A. Sperling · Banner Health$160,454,465
- Michael W Weiner · Northern California Institute Res &Educ$153,571,751
- Ronald C Petersen · Mayo Clinic Coll Of Medicine, Rochester$118,618,221
Research focus
CognitionGlycogen Storage Disease Type IiTreatment ResponseRegimenResponseImmunologicsMethotrexateInvestigationProphylacticProtocols DocumentationResidual StateSurvivorsImmune ResponseImmune ToleranceTreatment OutcomeInfancyLifeDoseNatural HistoryNeonatal ScreeningFollow-UpEnzyme Replacement TherapyHuman SubjectHuman Therapy Evaluation
Grant awards (24)
Long Term Follow-up and Treatment Outcomes for Individuals with Pompe Disease$67,126
U54 · FY2024 · NS · contact PI
Long Term Follow-up and Treatment Outcomes for Individuals with Pompe Disease$113,792
U54 · FY2023 · NS · contact PI
Long Term Follow-up and Treatment Outcomes for Individuals with Pompe Disease$115,731
U54 · FY2022 · NS · contact PI
Identifying Pathogenic Non-Coding Mutations in Rare Mendelian Disease$236,648
R21 · FY2020 · HG
Long Term Follow-up and Treatment Outcomes for Individuals with Pompe Disease$117,732
U54 · FY2020 · NS · contact PI
Identifying Pathogenic Non-Coding Mutations in Rare Mendelian Disease$196,489
R21 · FY2019 · HG
Long Term Follow-up and Treatment Outcomes for Individuals with Pompe Disease$122,785
U54 · FY2019 · NS · contact PI
Long-Term Follow-Up and Treatment Outcomes for Individuals with Infantile Pompe Disease$76,500
U54 · FY2018 · NS · contact PI
Long-Term Follow-Up and Treatment Outcomes for Individuals with Infantile Pompe Disease$77,781
U54 · FY2017 · NS · contact PI
Long-Term Follow-Up and Treatment Outcomes for Individuals with Infantile Pompe Disease$79,026
U54 · FY2016 · NS · contact PI
Long-Term Follow-Up and Treatment Outcomes for Individuals with Infantile Pompe Disease$80,252
U54 · FY2015 · NS · contact PI
Long-Term Follow-Up and Treatment Outcomes for Individuals with Infantile Pompe Disease$94,640
U54 · FY2014 · NS · contact PI
A RANDOMIZED, OPEN-LABEL, MULTICENTER, MULTINATIONAL, DOSE-RANGING STUDY OF THE$57,535
M01 · FY2005 · RR
CHOLINERGIC THERAPY IN CHILDREN WITH DOWN SYNDROME$3,138
M01 · FY2005 · RR
rhAcid Alpha-glucosidase (rhGAA) Tx in Pompe Disease$23,258
M01 · FY2004 · RR
Cholinergic Therapy in Children with Down Syndrome$8,458
M01 · FY2004 · RR
Cholinergic therapy in young adults with Down Syndrome$5,074
M01 · FY2004 · RR
A CLINICAL TRIAL OF DONEPEZIL FOR DOWN SYNDROME$114,524
K23 · FY2003 · RR
A CLINICAL TRIAL OF DONEPEZIL FOR DOWN SYNDROME$111,975
K23 · FY2002 · RR
DONEPEZIL THERAPY: DOWN SYNDROME: MENTAL RETARDAT, CLIN TRIAL &COGNITIVE STATUS$294,555
P41 · FY2001 · RR
A CLINICAL TRIAL OF DONEPEZIL FOR DOWN SYNDROME$109,500
K23 · FY2001 · RR
DONEPEZIL THERAPY: DOWN SYNDROME: MENTAL RETARDAT, CLIN TRIAL &COGNITIVE STATUS$8,917
P41 · FY2000 · RR
Phase IV crossover of cholinergic therapy in down syndrome$0
M01 · FY2000 · RR
Phase IV crossover of cholinergic therapy in down syndrome$0
M01 · FY2000 · RR